LIQID Medical is a South African clinical stage medical technology company based in Cape Town that focuses on developing innovative devices for the treatment of glaucoma, a leading cause of irreversible blindness worldwide. Founded by ophthalmologist Dr Daemon McClunan, the company is pioneering a new class of ocular implants designed to address the underlying causes of glaucoma by improving fluid drainage and pressure balance within the eye. Through advanced biomedical engineering and clinical research, the company aims to deliver more effective, affordable, and patient-friendly treatment options for individuals suffering from this chronic eye condition.
The company’s technology pipeline includes patented devices such as the OptiShunt, iPortVR, and iFlow, which are designed to enhance the safety and effectiveness of glaucoma surgery while reducing complications associated with traditional treatments. These implants aim to regulate intraocular pressure by directing excess fluid through natural anatomical pathways, improving patient outcomes and quality of life. By combining innovative design, clinical trials, and strategic investment, LIQID Medical is working to bring next generation ophthalmic solutions to global markets while strengthening South Africa’s role in medical device innovation.